Fundraising FoxCyclacel Pharmaceuticals
Berkeley Heights, US · Delaware corporation · 1 known investors
Find your way into Cyclacel Pharmaceuticals
Sign up to see every warm intro you have to Cyclacel Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Cyclacel Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
SR
PM
Paul McBarronExecutivePaul McBarron is a chartered accountant with over 30 years of experience in finance and operations leadership across biotechnology and pharmaceuticals. He previously served as COO and CFO of Cyclacel Pharmaceuticals (NASDAQ-listed), held senior roles at Shire Pharmaceuticals and Sanofi Winthrop, and has led companies through public listings, capital raises, and M&A integrations.
MH
Mark H. KirschbaumExecutive
GT
Gregory T. HradskyNamed on SEC filing
RJ
Robert J. SpeigelNamed on SEC filing
LS
Lloyd SemsNamed on SEC filing
Board
RS
Robert SpiegelBoard director
KW
Karin WalkerBoard director
CH
Christopher HenneyBoard director
SB
Samuel BarkerBoard director
BS
Brian SchwartzBoard director
KF
Kenneth FergusonBoard director
Investors · 1
Also in the syndicate · 1
H.C. Wainwright & Co.
Reported raises · per SEC filings
Form D private placements$18.1M disclosed across 4 of 6 rounds · 2020–2025
▶$1MraisedMar 2025 · 4 investors · BiotechnologyRule 506(b)
▶$1MraisedMar 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Avraham Ben-TzviDirector
- Kiu Cu SengExecutive Officer
- David NatanDirector
- Kwang Fock ChongDirector
- Datuk Dr. Doris Wong Sing EeExecutive Officer
- Offering amount
- $1M
- Amount sold
- $1M
- First sale
- Mar 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedFeb 2025 · 1 investors · BiotechnologyRule 506(b)
▶Undisclosed amountofferedFeb 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David NatanDirector
- David LazarExecutive Officer
- Avraham Ben-TzviDirector
- Paul McBarronDirector
- Samuel BarkerDirector
- Spiro RombotisDirector
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MofferedFeb 2025 · 1 investors · BiotechnologyRule 506(b)
▶$25MofferedFeb 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Paul McBarronDirector
- Avraham Ben-TzviDirector
- David NatanDirector
- Spiro RombotisDirector
- David LazarExecutive Officer
- Samuel BarkerDirector
- Offering amount
- $25M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.1MraisedNov 2024 · 1 investors · BiotechnologyRule 506(b)
▶$2.1MraisedNov 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Spiro RombotisExecutive Officer, Director
- Robert SpiegelDirector
- Karin WalkerDirector
- Christopher HenneyDirector
- Samuel BarkerDirector
- Brian SchwartzDirector
- Paul McBarronExecutive Officer, Director
- Kenneth FergusonDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- Sales commissions
- $190K
- Placement agents
- H.C. Wainwright & Co.
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8MraisedMay 2024 · 1 investors · BiotechnologyRule 506(b)
▶$8MraisedMay 2024 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Christopher HenneyDirector
- Karin WalkerDirector
- Spiro RombotisExecutive Officer, Director
- Robert SpiegelDirector
- Kenneth FergusonDirector
- Brian SchwartzDirector
- Paul McBarronExecutive Officer, Director
- Samuel BarkerDirector
- Offering amount
- $8M
- Amount sold
- $8M
- Sales commissions
- $640K
- Placement agents
- H.C. Wainwright & Co.
- First sale
- May 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7MraisedJan 2021 · 1 investors · BiotechnologyRule 506(b)
▶$7MraisedJan 2021 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Karin WalkerDirector
- Brian SchwartzDirector
- Christopher S. HenneyDirector
- Gregory T. HradskyDirector
- Spiro RombotisExecutive Officer, Director
- Robert J. SpeigelDirector
- Samuel L. BarkerDirector
- Paul McBarronExecutive Officer, Director
- Mark H. KirschbaumExecutive Officer
- Lloyd SemsDirector
- Offering amount
- $7M
- Amount sold
- $7M
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- How much funding has Cyclacel Pharmaceuticals raised?
- Cyclacel Pharmaceuticals has disclosed $18.1M raised across 4 of its 6 known rounds.
- Where is Cyclacel Pharmaceuticals headquartered?
- Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, US.